Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CASP6 | P55212 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24954764 | 0.84 | LMNA (0.60) | PLAUKDM4ELMNAPOLBCASP6 | |
| SCHEMBL30503638 | 0.82 | PLAU (1.00) | PLAUKDM4ELMNAPOLBCASP6 | |
| SCHEMBL3412309 | 0.82 | PLAU (1.00) | PLAUKDM4ELMNAPOLBCASP6 | |
| SCHEMBL198060 | 0.77 | BACE1 (0.50) | PLAUHRH3ALDH1A1HTR3ABACE1 | |
| SCHEMBL29447040 | 0.77 | BACE1 (0.50) | PLAUHRH3ALDH1A1HTR3ABACE1 | |
| SCHEMBL5394789 | 0.76 | KMT2A (0.82) | PLAUKDM4ELMNAPOLBCASP6 | |
| SCHEMBL31473182 | 0.76 | KMT2A (0.82) | PLAUKDM4ELMNAPOLBCASP6 | |
| SCHEMBL1598979 | 0.74 | BACE1 (0.39) | PLAUKDRBACE1NCK1EGFR | |
| SCHEMBL1133953 | 0.74 | NCK1 (0.64) | KDM4ELMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL789486 | 0.74 | BACE1 (0.64) | PLAUKDM4EHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240251795-A1 | METHOD FOR CONTROLLING DIAMIDE RESISTANT PESTS & COMPOUNDS THEREFOR | SYNGENTA CROP PROTECTION AG (CH) | 2024-08-01 | — | — | US | disclosed |
| EP-4387449-A1 | METHOD FOR CONTROLLING DIAMIDE RESISTANT PESTS & COMPOUNDS THEREFOR | Syngenta Crop Protection AG (CH) | 2024-06-26 | — | — | EP | disclosed |
| EP-4003976-B1 | PICOLINAMIDE DERIVATIVES USEFUL AS AGRICULTURAL FUNGICIDES | GLOBACHEM NV (BE) | 2024-04-24 | — | — | EP | disclosed |
| CN-117813006-A | Methods for controlling diamide-resistant pests and compounds thereof | 先正达农作物保护股份公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| CN-116323580-A | Conjugated degradation (EGFR) of EGFR inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| CN-1262540-C | Bicyclic androgen and progesterone receptor modulating compounds and methods | LIGAND PHARM INC (US) | 2006-07-05 | — | — | CN | disclosed |
| CN-1775759-A | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2006-05-24 | — | — | CN | disclosed |
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | LIGAND PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6964973-B2 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-11-15 | — | — | US | disclosed |
| WO-2005066132-A1 | THERAPEUTIC AGENTS I | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6566372-B1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer | LIGAND PHARMACEUTICALS INCORPORATED | 2003-05-20 | — | — | US | disclosed |
| CN-1382124-A | Bicyclic androgen and progesterone receptor modulating compounds and methods | LIGAND PHARM INC (US) | 2002-11-27 | — | — | CN | disclosed |
| EP-1212303-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | EGFR, ABL1, ERBB2 | PLAU 4096/4885KDM4E 2539/4885LMNA 4806/4885 |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | PLAU 2583/4885KDM4E 1783/4885LMNA 4230/4885 |
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | FSHR, CYP19A1, ESR2 | PLAU 1966/4885KDM4E 223/4885LMNA 1047/4885 |
| US-20240251795-A1 | METHOD FOR CONTROLLING DIAMIDE RESISTANT PESTS & COMPOUNDS THEREFOR | DDT, NOS1, SLC11A2 | PLAU 4644/4885KDM4E 2663/4885LMNA 2610/4885 |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | PLAU 1843/4885KDM4E 2209/4885LMNA 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.